RA
EW icon

Resolute Advisors’s Edwards Lifesciences EW Stock Holding History

Resolute Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-161
Closed -$18K – 304
2021
Q3 		$18K Hold
161
– – ﹤0.01% 238
2021
Q2 		$17K Hold
161
– – ﹤0.01% 207
2021
Q1 		$11K Buy
+161
New +$13.6K ﹤0.01% 223

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Resolute Advisors's EW Position: Q4 2021 in Review

Resolute Advisors sold out of Edwards Lifesciences (EW) in Q4 2021, closing a stake of 161 shares — an estimated $18K sold.

Resolute Advisors first reported a position in EW in Q1 2021 and held it in 3 quarters. The position peaked at $18K in Q3 2021. 1,319 funds tracked by Wall St. Rank hold EW as of Q4 2021.

  • Resolute Advisors reported no remaining Edwards Lifesciences position as of Q4 2021 after selling out during the quarter.
  • Resolute Advisors sold 161 Edwards Lifesciences shares in Q4 2021, an estimated $18K.
  • Resolute Advisors first reported a position in Edwards Lifesciences in Q1 2021 and held it in 3 quarters.
  • Resolute Advisors's Edwards Lifesciences position peaked at $18K in Q3 2021.
  • 1,319 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on Resolute Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.